key: cord-0723214-2w2rgkgp
authors: Gendrot, Mathieu; Andreani, Julien; Boxberger, Manon; Jardot, Priscilla; Fonta, Isabelle; Le Bideau, Marion; Duflot, Isabelle; Mosnier, Joel; Rolland, Clara; Bogreau, Hervé; Hutter, Sébastien; La Scola, Bernard; Pradines, Bruno
title: Antimalarial drugs inhibit the replication of SARS-CoV-2: an in vitro evaluation
date: 2020-09-08
journal: Travel Med Infect Dis
DOI: 10.1016/j.tmaid.2020.101873
sha: 31d30a8b3233fc81eafc300bb5245d6d041bb218
doc_id: 723214
cord_uid: 2w2rgkgp

In December 2019, a new severe acute respiratory syndrome coronavirus (SARS-CoV-2) causing coronavirus diseases 2019 (COVID-19) emerged in Wuhan, China. African countries see slower dynamic of COVID-19 cases and deaths. One of the assumptions that may explain this later emergence in Africa, and more particularly in malaria endemic areas, would be the use of antimalarial drugs. We investigated the in vitro antiviral activity against SARS-CoV-2 of several antimalarial drugs. Chloroquine (EC(50) = 2.1 μM and EC(90) = 3.8 μM), hydroxychloroquine (EC(50) = 1.5 μM and EC(90) = 3.0 μM), ferroquine (EC(50) = 1.5 μM and EC(90) = 2.4 μM), desethylamodiaquine (EC(50) = 0.52 μM and EC(90) = 1.9 μM), mefloquine (EC(50) = 1.8 μM and EC(90) = 8.1 μM), pyronaridine (EC(50) = 0.72 μM and EC(90) = 0.75 μM) and quinine (EC(50) = 10.7 μM and EC(90) = 38.8 μM) showed in vitro antiviral effective activity with IC(50) and IC(90) compatible with drug oral uptake at doses commonly administered in malaria treatment. The ratio C(lung)/EC(90) ranged from 5 to 59. Lumefantrine, piperaquine and dihydroartemisinin had IC(50) and IC(90) too high to be compatible with expected plasma concentrations (ratio C(max)/EC(90) < 0.05). Based on our results, we would expect that countries which commonly use artesunate-amodiaquine or artesunate-mefloquine report fewer cases and deaths than those using artemether-lumefantrine or dihydroartemisinin-piperaquine. It could be necessary now to compare the antimalarial use and the dynamics of COVID-19 country by country to confirm this hypothesis.

In Antimalarial drugs are potential candidates to be repurposed in both COVID-19 prophylaxis and therapy [3] . Are antimalarial drugs effective against SARS-CoV-2?

Chloroquine, a quinoline, has been shown to be effective in vitro against SARS-CoV-2 in Vero E6 cells (African green monkey kidney cells) with median effective concentration (EC 50 ) at micromolar range [4] [5] [6] . Hydroxychloroquine, an analogue of chloroquine used in autoimmune diseases such as rheumatoid arthritis and lupus, has also demonstrated in vitro antiviral activity against SARS-CoV-2 with EC 50 at micromolar range [4, 6, 7] . Twenty-three clinical trials have been conducted in China to investigate the efficacy and safety of chloroquine and hydroxychloroquine in the treatment of COVID-19 [8] [9] [10] . Although the clinical assay was not performed according to the randomized double blind method, preliminary data indicated that chloroquine phosphate has demonstrated efficacy in treatment of COVID-19 with few severe adverse reactions in more than 100 patients by shortening hospital stay and improving the clinical evolution [9] . Hydroxychloroquine could shorten time to clinical recovery [11, 12] . Effects of hydroxychloroquine were potentiated in vitro and in vivo by azithromycin [7, 13] . Ferroquine, a ferrocenic analogue of chloroquine with antimalarial activity [14] , was shown to be an effective inhibitor of SARS-CoV-1 replication with EC 50 of 1.4 µM [15] .

In 2002, the World Health Organization (WHO) recommended the use of artemisinin-based combination therapy (ACT) in the treatment of uncomplicated P. falciparum malaria (artemether-lumefantrine, artesunate-amodiaquine, dihydroartemisinin-piperaquine or artesunate-mefloquine). Marketed artemisinin derivatives exhibited in vitro anti-viral activity at micromolar concentrations against human cytomegalovirus [16] [17] [18] . Amodiaquine, a J o u r n a l P r e -p r o o f quinoleine antimalarial and one of the partner of artemisinin derivative in ACT, was found to be active in vitro at micromolar concentration against SARS-CoV-1 (2.5 µM) but was inactive in vivo on SARS-CoV-1 in BALB/c mice [19] . Another quinoline, mefloquine, which has been used in combination with artesunate for the treatment of uncomplicated falciparum malaria, exerts in vitro cytopathic effects on Vero cells infected by SARS-CoV-2 at 10 µM [20] . Pyronaridine, a quinoline component of the EU-approved antimalarial Pyramax (pyronaridine-artesunate), was effective in vitro against Ebola virus with EC 50 of 1.14 µM and protected mice when administered 1 hr after infection [21] .

Taken together, these reports suggest that antimalarial drugs may have antiviral effects and be effective against SARS-CoV-2. Chloroquine, hydroxychloroquine, ferroquine, quinine, mefloquine, desethylamodiaquine (the metabolite of amodiaquine), lumefantrine, pyronaridine, piperaquine and dihydroartemisinin (the metabolite of artemisinin derivatives)

were assessed in vitro against a clinically isolated SARS-CoV-2 strain.

All the drugs were provided by Sigma (Saint Louis, MO, USA). Stock solution of chloroquine diphosphate, hydroxychloroquine and ferroquine were prepared in water, in methanol for quinine, mefloquine, desethylamodiaquine, pyronaridine, piperaquine and dihydroartemisinin and in DMSO for lumefantrine. All the stock solutions were diluted in Minimum Essential Media (MEM, Gibco, ThermoFischer) in order to have 7 final concentrations ranging from 0.1 µM to 100 µM. The clinically isolated SARS-CoV-2 strain (IHUMI-3) [12] was maintained in production in Vero E6 cells (American type culture collection ATCC® CRL-1586™) in MEM with 4% of fetal bovine serum and 1% glutamine (complete medium).

In vitro cell viability evaluation on the VERO E6 cell line was performed according to the method described by Mosmann with slight modifications [22] . Briefly, 10 5 

Briefly, 96-well plates were prepared with 5.10 5 cells/mL of Vero E6 (200µL per well), as previously described [7] . Antimalarial concentrations were added 4 h before infection. Vero E Cells were infected with IHUMI-3 strain at an MOI of 0.25. After 48h post-infection, the replication was estimated by RT-PCR using the Superscrit III platinum one step with Rox kit (Invitrogene) after extraction with the BIoExtract SuperBall kit (Biosellal, Dardilly, France).

The primers used were previously described [23] . EC 50 and EC 90 were calculated with the J o u r n a l P r e -p r o o f inhibitory sigmoid E max model, which estimated the EC 50 and EC 90 through nonlinear regression by using a standard function of the R software (ICEstimator version 1.2). EC 50 value resulted in the mean of 6 different experimentations.

Selectivity index (SI) as ratio of CC 50 /EC 50 was estimated for each antimalarial drug. The expected maximum blood concentration (C max ) was estimated from literature for each drug at doses commonly administered in malaria treatment. The ratios C max /EC 50 and C max /EC 90 were estimated to find out if the effective concentration in plasma to cure SARS-CoV-2 is achievable in human. If data on drug accumulation into lung was available, the ratios C lung /EC 50 and C lung /EC 90 were calculated.

CC 50 , EC 50 , EC 90 and SI for each antimalarial drug are presented in Table 1 . Chloroquine, hydroxychloroquine, ferroquine, desethylamodiaquine, mefloquine and pyronaridine showed EC 50 and EC 90 at low micromolar range ( Table 1) . The ratio C max /EC 90 in blood ranged from 0.22 to 0.5 for chloroquine, hydroxychloroquine, mefloquine, pyronaridine and quinine (Fig.   1 ). But, these drugs were known to accumulate in lungs. The expected concentrations in lungs after an oral uptake at doses commonly administered in malaria treatment were sufficient to exert antiviral effects on SARS-CoV-2 (Fig. 2) .

Chloroquine and its analogues ferroquine and hydroxychloroquine showed in vitro activities at low-micromolar range with EC 50 [24] . Chloroquine has an excellent diffusion and tissue concentration which would lead to chloroquine levels 200 to 700 times higher in the lung than in the blood (a concentration which can go up to 280 mg/kg in the lung) [25] . An oral uptake of 400 mg of hydroxychloroquine led to a C max of 1.22 µM [26] . Hydroxychloroquine accumulated 30 times more in lungs than in blood (around 0.3 µM vs 7.8 µM at 6 hr) [27] . An oral uptake of 800 mg of ferroquine led to a mean C max (maximum blood concentration) value of 155 ng/ml (around 0.6 µM) and t 1/2 (elimination half-life) of 10.9 days [28] . No data is available on ferroquine accumulation in lungs. However, as ferroquine is an analogue of chloroquine, we can assume that it may accumulate at least 10 times than in blood. The antiviral activity of chloroquine and its analogues against SARS-CoV-2 are compatible with oral uptake at doses administered in malaria treatment. Chloroquine and hydroxychloroquine inhibited SARS-CoV-2 entry [4, 5] . Chloroquine impaired the terminal glycosylation of ACE-2 receptor required for virus entry that resulted in reduced binding affinities between SARS-CoV-1 and its ACE-2 receptor and blocked SARS-CoV-1 entry in human cells [29] . The spike viral protein of SARS-CoV-2 used the ACE-2 receptor for entry, but also sialic acids and gangliosides. In silico analyses showed that the viral spike protein was not able to bind gangliosides in the presence of chloroquine or hydroxychloroquine [30] . Additionally, the ORF8 viral protein could bind to the porphyrin. At the same time, viral orflab, ORF10 and J o u r n a l P r e -p r o o f ORF3a proteins could attack the heme to dissociate the iron to form the porphyrin and inhibit the human heme metabolism leading to a decrease of hemoglobin amount which carry oxygen and carbon dioxide. Chloroquine could inhibit the binding of ORF8 to porphyrin and prevent the attack of the 1-beta chain of hemoglobin by orflab, ORF10 and ORF3a proteins [31] .

Besides its antiviral activity, chloroquine and hydroxychloroquine have anti-inflammatory effects by decreasing the expression of various pro-inflammatory cytokines including interleukin 6 (IL6), tumor necrosis factor-alpha (TNF) and interferon gamma (INFγ) by mononuclear cells [32] . These cytokines were considerably increased in the cytokine storm due to COVID-19 [33] . Many clinical trials on hydroxychloroquine alone or in combination with azithromycin to treat COVID-19 are in progress. The efficacy of hydroxychloroquine alone or in combination with azithromycin has been controversial. Hydroxychloroquine showed antiviral activity Vero E6 cells (African green monkey kidney cells) [4] [5] [6] 34] but not in a model of reconstituted airway epithelium [34] . Moreover, neither hydroxychloroquine alone or in combination with azithromycin showed significant effect on the viral load levels in comparision with placebo [34] . Some studies showed that early treatment with hydroxychloroquine alone or in combination with azithromycin was associated with a reduced risk of hospitalization, reduced risk of death and shorter duration of viral presence [35] [36] [37] .

Early treatment with hydroxychloroquine decreased the level of secreted inflammatory cytokines (IL6, TNF and INFγ) [40] . Conversely, some studies showed that treatment of mildto-moderate or mild-to-severe COVID-19 with hydroxychloroquine alone or in combination with azithromycin did not improve clinical status or duration of viral shedding in comparison with standard care [41] [42] [43] [44] [45] . Moreover, therapeutic interventions using high dosage chloroquine and/or in combination with macrolides may have severe side-effects including cardiac toxicity.

A prophylactic approach with chloroquine at lower dosage could be administrated in vulnerable persons with comorbidities at-risk of severe COVID-19 or in health workers [46] . Chloroquine at 100 mg daily was used for decades for the antimalarial chemoprophylaxis.

Several trials on prophylaxis with chloroquine are currently in progress (NCT04349371, NCT04303507). Chloroquine could be evaluated alone or in combination with antibiotics like doxycycline in prophylactic trials. Indeed doxycycline showed in vitro antiviral activity against SARS-CoV-2 (EC 50 = 5.6 µM) and low toxicity [47] . Doxycycline at 100 mg daily was used for many years for the antimalarial chemoprophylaxis and combining chloroquine to doxycycline in daily prophylaxis did not increase the risk of adverse effects [48] .

Desethylamodiaquine, the metabolite of amodiaquine, showed the best in vitro efficacy with EC 50 of 0.52 ± 0.2 µM (SI = 166). Amodiaquine was used in combination with artesunate in the treatment of uncomplicated malaria in Africa (306 mg amodiaquine base and 100 mg artesunate). Amodiaquine given at 612 mg day led to a plasma concentration of 753 ng/ml of desethylamodiaquine (around 1.9 µM) and a t 1/2 of 8.9 days [49] . About 0.07% of the administered dose was found in rat lung [50] . This suggests that for an uptake of 612 mg in human, 428 µg would be found in lungs. Amodiaquine, was found to be active also in vitro against SARS-CoV-1 with EC 50 of 2.5 µM but was inactive in vivo on SARS-CoV-1 in BALB/c mice [19] . Chloroquine, effective in vitro with EC 50 of 2.5 µM, was also inactive in vivo on SARS-CoV-1 in BALB/c mice. Amodiaquine also inhibited dengue virus type 2 replication with EC 50 of 1.08 µM and EC 90 of 2.69 µM [51] . The antiviral activity of desethylamodiaquine against SARS-CoV-2 is compatible with oral uptake of amodiaquine at doses commonly administered in malaria treatment. Amodiaquine can only be recommended as treatment and not as prophylaxis due to risk of hepatitis and agranulocytosis during longterm administration [52] . These results are consistent with previous study which showed that mefloquine at 10 µM inhibited completely cytopathic effect onVero E6 cells infected by SARS-CoV-2 [20] .

Mefloquine administered at malaria therapeutic dose (1250 mg) lead to a blood concentration of 1,648 ng/ml (around 4 µM) in healthy males [53] . A study on postmortem cases showed that mefloquine levels are 10 times higher in the lung than in the blood (a concentration which can go up to 180 mg/kg in the lung) [54] . The antiviral activity of mefloquine against SARS-CoV-2 is compatible with malaria oral therapeutic doses. But mefloquine can cause neuropsychiatric adverse effects [55] .

Pyronaridine showed effective antiviral activity with EC 50 of 0.72 µM and EC 90 of 0.75 µM.

Pyronaridine tetraphosphate given at 720 mg day led to a plasma concentration of 271 ng/ml (around 0.3 µM) in human and a t 1/2 of 33.5 days [56] . A single oral dose of 2 mg (10 mg/kg) in rats led to a blood C max of 223 ng/ml and a lung C max of 36.4 µg/g (165 more concentrated) [57] . The antiviral activity of pyronaridine against SARS-CoV-2 is compatible with malaria oral therapeutic doses. Acute and sub-acute toxicity was less than that of chloroquine. Cardiovascular toxicity was also less than that of chloroquine [58] . Pyronaridine was well tolerated: around 38% of adverse events versus 56% for chloroquine [59] .

Quinine showed medium antiviral in vitro activity with EC 50 of 10.7 ± 3.0 µM and EC 90 of 38.8 ± 34 µM. A 600 mg single oral dose of quinine sulphate led to blood C max around 3.5 mg/l (around 8.5 µM) [60] . In rat, after intravenous dose of 10 mg/kg of quinine, the observed concentration lung/blood ratio was 246 [61] . The in vitro effective concentration in lungs to cure SARS-CoV-2 is achievable in human. If its clinical efficacy in human would be confirmed, quinine could be administered in intravenous in patients before cytokine storm.

Quinine can cause haemolytic anemia in patients with G6PD deficiency and severe side-J o u r n a l P r e -p r o o f effects including cardiac toxicity [52] . Additionally, quinine could be associated with doxycycline against COVID-19, as is done in malaria treatment [62] .

Lumefantrine, piperaquine and dihydroartemisinin showed low antiviral activity with EC 50 of 24.7, 33.4 and 20.1 µM, respectively. A single oral dose of lumefantrine (480 mg) led to C max of 1.1 µM [63] . A single oral dose of 1280 mg of piperaquine and 160 mg of dihydroartemisinin in fed participants led to plasma C max of 596 ng/ml and 324 ng/ml, respectively [64] . No data is available on drug accumulation in lungs for these antimalarial.

The ratio C max /EC 50 or C max /EC 90 were too low to reach effective concentrations to inhibit SARS-CoV-2 in human. However, ACT (artemether-lumefantrine, artesunate-amodiaquine, dihydroartemisinin-piperaquine, artesunate-mefloquine or artesunate-pyronaridine), evaluated at plasma concentrations expected after oral uptake at recommended doses used in uncomplicated malaria treatment, showed an in vitro inhibition of SARS-CoV-2 replication that ranged from 30 to 70% [65] . The combination mefloquine-artesunate was found to be the most effective in vitro against SARS-CoV-2.

Chloroquine, hydroxychloroquine, ferroquine, desethylamodiaquine, mefloquine, pyronaridine and quinine showed in vitro antiviral effective activity against SARS-CoV-2 with IC 50 and IC 90 compatible with drug oral uptake at doses commonly administered in malaria treatment. These in vitro activities are higher than those obtained with drugs which J o u r n a l P r e -p r o o f 

A new coronavirus associated with human respiratory disease in China

Comparative genetic abalysis of the novel coronavirus (2019-nCoV/SARS-CoV-2) receptor ACE2 in different populations

Repurposing antimalarials and other drugs for COVID-19

Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro

Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCov) in vitro

In vitro testing of hydroxychloroquine and azithromycin on SARS-CoV-2 shows synergistic effect

A systematic review on the efficacy and safety of chloroquine for the treatment of COVIS-19

Breakthrough: Chloroquine phosphate has shown apparent efficacy in the treatment of COVID-19 associated pneumonia in clinical studies

Of chloroquine and COVID-19

Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial

Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial

with at least a six-day follow up: an observational study

Ferrocene-chloroquine analogues as antimalarial agents: in vitro activity of ferrochloroquine against 103 Gabonese isolates of Plasmodium falciparum

Design and synthesis of hydroxyferroquine derivatives with antimalarial and antiviral activities

Synthesis of artemisinin-derivated di/tri-mers and dendrimers, investigation of their activity against P. falciparum and cytomegalovirus, and insights into their mechanisms of action

The artemisinin derivative artemisone is a potent inhibitor of human cytomegalovirus replication

Inhibition of human cytomegalovirus replication by artemisinins: effects mediated through cell cycle modulation

Evaluation of immunomodulators, interferons and known in vitro SARS-CoV inhibitors for inhibition of SARS-CoV replication in BALB/c mice

Repurposing of clinically approved drugs for treatment of coronavirus disease 2019 in a 2019-novel J o u r n a l P r e -p r o o f coronavirus (2019-nCoV) related coronavirus model

Repurposing the antimalarial pyronaridine tetraphosphate to protect against Ebola virus infection

Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays

Rapid viral diagnosis and ambulatory management of suspected COVID-19 cases presenting at the infection diseases referral hospital

Les intoxications aiguës à la chloroquine: aspects cliniques et analytiques

Chloroquine: a review

Therapy and pharmacological properties of hydroxychloroquine and chloroquine in the treatment of systemic lupus erythematosus, rheumatoid arthritis and related diseases

Simultaneous quantification of hydroxychloroquine and its metabolites in mouse blood and tissues using LC-ESI-MS/MS: An application for pharmacokinetic studies

A Phase II pilot trial to evaluate safety anf efficacy of ferroquine against early Plasmodium falciparum in a induced blood-stage malaria infection study

Chloroquine is a potent inhibitor of SARS coronavirus infection and spread

Structural and molecular modeling studies reveals a new mechanism of action of chloroquine and hydroxychloroquine against SARS-CoV-2 infection

COVID-19: Attacks the 1-beta chain of hemoglobin and captures the porphyrin to inhibit human heme metabolism

Chloroquine and hydroxychloroquine equally affect tumor necrosis factor-alpha, interleukin 6, and interferon gamma production by peripheral blood mononuclear cells

Dysregulation of immune response in patients with COVID-19 in Wuhan, China

Hydroxychloroquine use against SARS-CoV-2 infection in non-human primates

Early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: A retrospective analysis of 1061 cases in Marseille, France

IHU COVID-19 Task Force. Outcomes of 3,737 COVID-19 patients treated with hydroxychloroquine/azithromycin and other regimens in Marseille, France: A retrospective analysis

Treatment with hydroxychloroquine, azithromycin, and combination in patients hospitalized with COVID-19

Early hydroxychloroquine administration for rapid severe acute respiratory syndrome coronavirus 2 eradication

Hydroxychloroquine treatment in COVID-19: a descriptive observational analysis of 30 cases from a single center in Wuhan

Beneficial effects exerted by hydroxychloroquine in treating COVID-19 patients via protecting multiple organs

Hydroxychloroquine with or without azithromycin in mild-to-moderate Covid-19

Effects of hydroxychloroquine on Covid-19 in intensive care unit patients: preliminary results

Compassionate use of hydroxychloroquine in clinical practice for patients with mild to severe Covid-19 in a French university hospital

Vall-Mayans M. Hydroxychloroquine for early treatment of adults with mild-Covid-19: A randomized-controlled trial

Hydroxychloroquine in the treatment of COVID-19: A multicenter randomized controlled study

Chloroquine as prophylactic agent against COVID-19?

In vitro antiviral activity of doxycycline against SARS-CoV-2

Doxycycline-chloroquine vs. doxycycline placebo for malaria prophylaxis in nonimmune soldiers: a double-blind randomized field trial in sub-Saharan Africa

Validation and pharmacokinetic application of a high-performance liquid chromatographic technique for determining the concentrations of amodiaquine and its metabolite in plasma of patients treated J o u r n a l P r e -p r o o f with oral fixed-dose amodiaquine-artesunate combination in areas of malarial endemicity

Tissue distribution and excretion of amodiaquine in the rat

Amodiaquine, an antimalarial drug, inhibits dengue virus type 2 replication and infectivity

Antimalarial drug toxicity: A review

Gender-specific distribution of mefloquine in the blood following the administration of therapeutic doses

Mefloquine distribution in postmortem cases

Neuropsychiatric problems in 2,500 long-term young travelers to the tropics

Mass balance and metabolism of the antimalarial pyronaridine in healthy volunteers

Absorption, distribution, excretion, and pharmacokinetics of 14C-pyronaridine tetraphosphate in male and female Sprague-Dawley rats

Review of pyronaridine ant-malarial properties and product characteristics

Pyronaridine: A new antimalarial drug

Pharmacokinetic parameters of quinine in healthy subjects and in patients with uncomplicated malaria in Nigeria: Analysis of data using a population approach

Comparative uptake of quinine and quinidine in rat lung

Artemetherlumefantrine and liver enzyme abnormalities in non-severe Plasmodium falciparum malaria in returned travellers: a retrospective comparative study with quinine-doxycycline in Portuguese centre

Comparable lumefantrine oral bioavailability when co-administered with oilfortified maize porridge or milk in healthy volunteers

Effect of food on the pharmacokinetics of piperaquine and dihydroartemisinin

Antimalarial artemisininbased combination therapies (ACT) and COVID-19 in Africa: In vitro inhibition of SARS-CoV-2 replication by mefloquine-artesunate

Remdesivir, lopinavir, emetine, and homoharringtonine inhibits SARS-CoV-2 replication in vitro

Hydroxychloroquine in the treatment of COVID-19: How to use it waiting for conclusive scientific evidence

Chloroquine and hydroxychloroquine as a repurposed agent against COVID-19: a narrative review